In Depth 7 Mar 2024
Can AbbVie’s legacy live beyond its once best-selling drug Humira?
The sales of AbbVie’s Humira, once a best-seller, have dropped. Now, with a new CEO announced, things are about to change for the company.
Mergers & acquisitions
- Latest Posts
Best in Biotech 5 Mar 2024
Fourteen biotech companies with market caps exceeding $100 billion
Discover the biotech leaders with a market capitalization exceeding $100 billion, driving innovation and shaping tomorrow’s breakthroughs.
In Depth 27 Feb 2024
Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?
Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition.
In Depth 9 Feb 2024
Biotech job market 2024: what to expect?
The past year saw pipeline cuts and downsizing plans strike the biotech industry. Does the biotech job market seem to be looking up this year?
In Depth 25 Jan 2024
The trends that will shape the biotech industry in 2024
What does 2024 hold for the biotech industry? Delve into the experts’ insight on the biotech trends that will shape 2024.
News and Trends 8 Jan 2024
Is the biotech industry poised for recovery in 2024?
The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery.
ADVERTISEMENT
ADVERTISEMENT
Weekly Roundup 15 Dec 2023
Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
Weekly Roundup 8 Dec 2023
Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer
What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.
News and Trends 1 Dec 2023
Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered
Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […]
Weekly Roundup 24 Nov 2023
Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA
Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […]
News and Trends 20 Nov 2023
M&As: what’s up with the ADC buying spree?
Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]
Weekly Roundup 10 Nov 2023
Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs
You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]
ADVERTISEMENT